Santarus has initiated patient enrolment in the Phase IIa study designed to assess the safety and tolerability of repeat subcutaneous (SC) doses of SAN-300 in patients with active rheumatoid arthritis with inadequate response to disease-modifying anti-rheumatic drugs.
The randomised, double-blind study will enrol up to 90 patients in five groups. There is a four week follow-up period for safety and efficacy assessments.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The primary objective of the placebo-controlled, multiple ascending dose Phase IIa study is to assess the safety and tolerability of repeat doses of SAN-300 SC in patients with active RA.
Secondary objectives include pharmacokinetics and pharmacodynamics, preliminary efficacy and immunogenicity.
Planned doses of SAN-300 to be studied include 0.5mg/kg SC once weekly, 1.0mg/kg SC once weekly, 2.0mg/kg SC every other week, 2.0mg/kg SC once weekly, and 4.0mg/kg SC every other week.
All patients from each group will receive SAN-300 or placebo at their assigned dose and administration frequency for a total of six weeks.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataSAN-300 is an investigational drug that is a humanised anti-VLA-1 monoclonal antibody and an inhibitor of VLA-1, also known as a1ß1 integrin.
According to Santarus, SAN-300 is a drug candidate that has potential application in multiple inflammatory and autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma and organ transplantation.
Santarus has already completed a Phase I clinical programme with SAN-300, which it had initiated in March 2011.
The placebo-controlled, blinded, dose-escalation study was conducted in Australia and the single-dose study enrolled approximately 60 subjects, including healthy volunteers and two cohorts of patients with rheumatoid arthritis.
Objectives of the Phase I clinical study included the assessment of safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of SAN-300.
Santarus acquired the exclusive worldwide rights to SAN-300 in September 2010, through the acquisition of closely held Covella Pharmaceuticals, and a related amended licensing agreement with Biogen Idec.
Biogen Idec has initially developed the anti-VLA-1 antibody and licensed to Covella in January 2009.
Image: X-ray of the hand in rheumatoid arthritis. Photo: courtesy of Braegel.
